Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on an Immune Checkpoint Inhibitor (FORTIFY)

NCT06270706 is registered in ClinicalTrials.gov with Pliant Therapeutics, Inc. as lead sponsor.

NCT NCT06270706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06270706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on an Immune Checkpoint Inhibitor (FORTIFY)
Lead sponsor
Pliant Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 30, 2023
Completion date
June 30, 2030
Enrollment
124 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumor